Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs

被引:12
作者
Brogden, KA
DeBey, B
Audibert, F
Lehmkuhl, H
Chedid, L
机构
[1] UNIV CALIF TULARE,SCH VET MED,VET DIAGNOST LAB,TULARE,CA
[2] SYN SA,VAC,F-75015 PARIS,FRANCE
关键词
Pasteurella haemolytica; pneumonic pasteurellosis; capsular polysaccharide; muramyl dipeptide; vaccine;
D O I
10.1016/0264-410X(95)00109-E
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The capsular polysaccharide (CP) of Pasteurella haemolytica serotype Al is a poor immunogen for the prevention of pneumonic pasteurellosis of ruminants. To improve CP immunogenicity, vaccines were prepared with 1.0 mg CP dose(-1) with and without the synthetic adjuvant, muramyl dipeptide (MDP; range 0.2-1.0 mg) or a lipophilic derivative, MDP-sn-glyceryl-dipalmitoyl (MDP-GDP; range 0.1-1.0 mg). The optimum effective concentration of adjuvant was first determined in lambs and calves and then the efficacy of CP+0.5 mg MDP and CP+1.0 mg MDP-GDP was compared with that of two commercial vaccines in calves. After immunization with CP, antibody titers in lambs and calves were typical of that seen with polysaccharide immunogens and characterized by an early IgM response followed by later IgG1 and IgG2 responses. CP + MDP or MDP-GDP vaccines induced significantly higher IgM, IgG1, and IgG2 titers. After transtracheal challenge of immunity with P. haemolytica serotype Al, extensive pulmonary consolidation containing P. haemolytica (10(6)-10(8) c.f.u. g(-1)) was seen in all lambs and calves vaccinated with CP alone and was Mot significantly different (P<0.05) from the consolidation and concentrations of organisms in nonvaccinated challenge controls. In lambs, vaccines containing 1.0 mg: CP+0.05 mg MDP or MDP-GDP significantly reduced pulmonary consolidation and concentrations of P. haemolytica in lung lesions. In calves, vaccines containing 0.2 mg MDP, 0.5 mg MDP, or 1.0 mg MDP-GDP also significantly reduced pulmonary consolidation and concentrations of P. haemolytica in lung lesions. Vaccines containing CP+0.5 mg MDP and CP+1.0 mg MDP-GDP induced high titer bactericidal antibodies by 7 days and were move efficacious than two commercial vaccines. Potentiation of CP with MDP or MDP-GDP has great promise in furthering the potential of CP as a vaccine immunogen for the prevention of pneumonic pasteurellosis.
引用
收藏
页码:1677 / 1684
页数:8
相关论文
共 34 条
[1]  
ADLAM C, 1984, J GEN MICROBIOL, V130, P2415
[2]  
ANDREWS J, 1986, THESIS MICHIGAN STAT
[3]   ADJUVANTS - CURRENT STATUS, CLINICAL PERSPECTIVES AND FUTURE-PROSPECTS (REPRINTED FROM TRENDS IN PHARMACOLOGICAL SCIENCES, VOL 14, PG 174-178, 1993) [J].
AUDIBERT, FM ;
LISE, LD .
IMMUNOLOGY TODAY, 1993, 14 (06) :281-284
[4]  
BIGNON J, 1976, AM REV RESPIR DIS, V113, P109
[5]  
BROGDEN KA, 1990, AM J VET RES, V51, P200
[6]   RESISTANCE TO HOST IMMUNE DEFENSE-MECHANISMS AFFORDED BY CAPSULAR MATERIAL OF PASTEURELLA-HAEMOLYTICA, SEROTYPE-1 [J].
CHAE, CH ;
GENTRY, MJ ;
CONFER, AW ;
ANDERSON, GA .
VETERINARY MICROBIOLOGY, 1990, 25 (2-3) :241-251
[7]  
CONFER AW, 1989, AM J VET RES, V50, P98
[8]  
CONFER AW, 1985, AM J VET RES, V46, P342
[9]  
CONFER AW, 1988, J AM VET MED ASSOC, V193, P1308
[10]   EFFICACY OF RECOMBINANT LEUKOTOXIN IN PROTECTION AGAINST PNEUMONIC CHALLENGE WITH LIVE PASTEURELLA-HAEMOLYTICA-A1 [J].
CONLON, JA ;
SHEWEN, PE ;
LO, RYC .
INFECTION AND IMMUNITY, 1991, 59 (02) :587-591